Alnylam Pharmaceuticals (ALNY) Other Accumulated Expenses (2013 - 2018)

Alnylam Pharmaceuticals has reported Other Accumulated Expenses for 6 years, with the latest figure at $23.6 million in Q4 2018.

• For the quarter ending Q4 2018, Other Accumulated Expenses rose 117.66% year-over-year to $23.6 million; the trailing twelve-month figure through Dec 2018 stood at $23.6 million (up 117.66% YoY), and the FY2018 full-year result was $23.6 million, up 117.66% from the prior year.
• Other Accumulated Expenses for Q4 2018 stood at $23.6 million, up from $10.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $25.4 million in Q1 2014, with the low at $3.8 million in Q4 2014.
• Historically, Other Accumulated Expenses has averaged $13.5 million across 5 years, with a median of $11.7 million in 2016.
• Annual changes were most pronounced in 2016 — Other Accumulated Expenses jumped 154.34% — and 2017, when it fell 14.02%.
• Alnylam Pharmaceuticals' Other Accumulated Expenses stood at $3.8 million in 2014, then jumped by 30.38% to $5.0 million in 2015, then surged by 154.34% to $12.6 million in 2016, then slipped by 14.02% to $10.9 million in 2017, then jumped by 117.66% to $23.6 million in 2018.
• The last three Other Accumulated Expenses figures came in at $23.6 million (Q4 2018), $10.9 million (Q4 2017), and $12.6 million (Q4 2016), per Business Quant data.